Christi M Terry1, Yuxia He2, Alfred K Cheung3. 1. Division of Nephrology & Hypertension, Internal Medicine, School of Medicine, University of Utah, 30 N. 1900 E. Room 4R312, Salt Lake City, UT 84132, USA. Electronic address: christi.terry@hsc.utah.edu. 2. Division of Nephrology & Hypertension, Internal Medicine, School of Medicine, University of Utah, 30 N. 1900 E. Room 4R312, Salt Lake City, UT 84132, USA. 3. Division of Nephrology & Hypertension, Internal Medicine, School of Medicine, University of Utah, 30 N. 1900 E. Room 4R312, Salt Lake City, UT 84132, USA; Medicine, Veterans Affairs Salt Lake City Healthcare System, 500 Foothill Dr., 151N, Salt Lake City, UT 84108, USA.
Abstract
INTRODUCTION: Dysfunction of indwelling central venous catheters (CVC) due to tissue ingrowth or clotting is common. The study objective was to determine if the oral anticoagulant rivaroxaban (RIVA) improved CVC patency and inflammation in mice. MATERIALS AND METHODS: Polyurethane catheters (0.5cm length) were placed unilaterally into the external jugular vein (EJV) of mice, which subsequently underwent daily gavage with either vehicle or RIVA (5mg/kg). CVC patency, as assessed by B-mode and Doppler ultrasound, and hematocrit were measured at 3, 7, 14 or 21days (n=8-11 mice/group/time-point). Plasma monocyte chemotactic protein-1 (MCP-1) levels were assessed by ELISA, EJV matrix metalloproteinase-9 (MMP-9) levels by western immunoblotting, and cell proliferation (anti-Ki67), macrophage infiltration (anti-MAC387) by immunostaining of EJV tissues. RESULTS AND CONCLUSIONS: CVC patency was significantly improved in RIVA-treated mice compared to vehicle-treated (93.8% vs. 62.9%) with the probability of patency in RIVA-treated mice being 1.5 times that in vehicle-treated (relative risk [RR], 1.50, 95% confidence interval [CI], 1.14-1.95, p=0.002). Plasma MCP-1 levels were lower in RIVA-treated mice vs. vehicle-treated at 21days (389±260 vs. 804±292ng/mL, p=0.005). Cell proliferation was less at day 7 in EJV from the RIVA-treated mice than vehicle-treated (5.0%±3.0 vs. 11.5%±3.6, p=0.0006), as were MMP-9 protein levels. There were no differences in hematocrit between vehicle and RIVA-treated groups at any time point. In conclusion, these data indicate RIVA lowers inflammation and improves CVC patency in a mouse model, supporting future studies to assess RIVA for improving CVC patency in patients.
INTRODUCTION: Dysfunction of indwelling central venous catheters (CVC) due to tissue ingrowth or clotting is common. The study objective was to determine if the oral anticoagulant rivaroxaban (RIVA) improved CVC patency and inflammation in mice. MATERIALS AND METHODS:Polyurethane catheters (0.5cm length) were placed unilaterally into the external jugular vein (EJV) of mice, which subsequently underwent daily gavage with either vehicle or RIVA (5mg/kg). CVC patency, as assessed by B-mode and Doppler ultrasound, and hematocrit were measured at 3, 7, 14 or 21days (n=8-11 mice/group/time-point). Plasma monocyte chemotactic protein-1 (MCP-1) levels were assessed by ELISA, EJVmatrix metalloproteinase-9 (MMP-9) levels by western immunoblotting, and cell proliferation (anti-Ki67), macrophage infiltration (anti-MAC387) by immunostaining of EJV tissues. RESULTS AND CONCLUSIONS: CVC patency was significantly improved in RIVA-treated mice compared to vehicle-treated (93.8% vs. 62.9%) with the probability of patency in RIVA-treated mice being 1.5 times that in vehicle-treated (relative risk [RR], 1.50, 95% confidence interval [CI], 1.14-1.95, p=0.002). Plasma MCP-1 levels were lower in RIVA-treated mice vs. vehicle-treated at 21days (389±260 vs. 804±292ng/mL, p=0.005). Cell proliferation was less at day 7 in EJV from the RIVA-treated mice than vehicle-treated (5.0%±3.0 vs. 11.5%±3.6, p=0.0006), as were MMP-9 protein levels. There were no differences in hematocrit between vehicle and RIVA-treated groups at any time point. In conclusion, these data indicate RIVA lowers inflammation and improves CVC patency in a mouse model, supporting future studies to assess RIVA for improving CVC patency in patients.
Authors: Sandrine Lavau-Denes; P Lacroix; A Maubon; P M Preux; D Genet; L Vénat-Bouvet; J L Labourey; J Martin; P Slaouti; N Tubiana-Mathieu Journal: Cancer Chemother Pharmacol Date: 2013-05-01 Impact factor: 3.333
Authors: Mark Y Chan; Min Lin; Joseph Lucas; Arthur Moseley; J Will Thompson; Derek Cyr; Hitoshi Ueda; Mariko Kajikawa; Thomas L Ortel; Richard C Becker Journal: Thromb Haemost Date: 2012-10-10 Impact factor: 5.249
Authors: Karim C El Kasmi; Aimee L Anderson; Michael W Devereaux; Sophie A Fillon; J Kirk Harris; Mark A Lovell; Milton J Finegold; Ronald J Sokol Journal: Hepatology Date: 2012-03-18 Impact factor: 17.425
Authors: Florian Lordick; Markus Hentrich; Thomas Decker; Michael Hennig; Hans Pohlmann; Reiner Hartenstein; Christian Peschel Journal: Br J Haematol Date: 2003-03 Impact factor: 6.998
Authors: Rupert M Bauersachs; Anthonie Wa Lensing; Martin H Prins; Dagmar Kubitza; Ákos F Pap; Hervé Decousus; Jan Beyer-Westendorf; Paolo Prandoni Journal: Thromb J Date: 2014-11-24
Authors: Liam A Evans; Colleen Tansey; Melissa Wiebe; Caroline Q Sloan; Jeffrey E Patlogar; Sarah Northcutt; Lisa A Murphy; Reid K Nakamura Journal: Vet Med Sci Date: 2019-03-08
Authors: Pietro Scicchitano; Marco Tucci; Maria Consiglia Bellino; Francesca Cortese; Annagrazia Cecere; Micaela De Palo; Francesco Massari; Pasquale Caldarola; Francesco Silvestris; Marco Matteo Ciccone Journal: Cardiovasc Drugs Ther Date: 2021-06 Impact factor: 3.727